Gland Pharma announces Rs. 400 cr investment in Genome Valley

HYDERABAD: Gland Pharma announced an investment of over Rs. 400 crores in Genome Valley on Monday to expand their existing facility's ability to manufacture biologicals, biosimilars, antibodies, and recombinant insulin. The expanded facility would have the capacity to employ more than 500 competent, talented, and semi-skilled workers, largely from the surrounding area.

The company had established their biopharmaceutical facility in February 2022 at Genome Valley with an investment of Rs 300 crores to manufacture Vaccines, Biologicals, Biosimilar, Antibodies and others. Recruitment of 200 manpower already completed in the facility. The expanded site was envisaged to meet the national and international regulations to be followed in the manufacturing of the biological products as applicable and shall be built under the GMP guidelines applicable for the respective product lines.

The announcement came following a meeting between Minister KT Rama Rao and Srinivas Sadu, Managing Director and Chief Executive Officer of Gland Pharma. Jayesh Ranjan IAS, Principal Secretary, Industries and Commerce Department, and Shakthi M Nagappan, Chief Executive Officer, Telangana Life sciences, were also present at the meeting.

Gland Pharma Limited is a generic injectable focused pharmaceutical firm that has been striving for over forty years to provide quality goods for people's health care needs. They currently run eight production plants in India, with a total capacity of around 1,000 million units. These include four facilities with 28 final formulation production lines and four Active Pharmaceutical Ingredient (API) facilities, including the Genome Valley facility for biopharmaceutical Drug Substance (DS).

Genome Valley is India's first organised cluster for Life Sciences R&D and Clean Manufacturing operations, with world-class infrastructural facilities such as Industrial/Knowledge Parks, Special Economic Zones (SEZs), multi-tenanted dry and wet laboratories, and incubation facilities. It is home to over 200 enterprises with a scientific workforce of around 15,000 employees, including prominent worldwide names such as Novartis, GSK, Ferring Pharma, Chemo, DuPont, Ashland, United States Pharmacopeia, and Lonza, among many more.

Chief Executive Officer and Managing Director of Gland Pharma, Srinivas Sadu said, “We are delighted to collaborate with the Government of Telangana on its vision of making the State a hub for global pharmaceutical requirements, by expanding our Bio -CDMO facilities in Shamirpet. This project investment is estimated to be about Rs 400 crores and expected to generate employment to about 500 personnel”.

Minister K.T Rama Rao said that “I am delighted that Gland Pharma will be investing Rs. 400 Crores in expanding their footprint in Hyderabad and will create 500 more jobs in Telangana. I am also excited that the expansion will be focussed on advanced areas like Biologicals, Biosimilar, Antibodies and recombinant Insulin, all of which are areas where the State is focussed on building capabilities and consolidating our leadership position. This expansion truly demonstrates the strength of life sciences ecosystem in the city and Genome Valley”.